Mubadala Bio Signs Deal to Distribute Baynounah's AI-Designed Diagnostic Kits
Al Ittihad Drug Store will take the Abu Dhabi biotech's locally made molecular test kits to healthcare providers in the UAE and the wider region.
By Nakoda News Desk
·2 min read
Prefer Nakoda News on Google

Mubadala Bio, the pharmaceutical arm of Abu Dhabi's Mubadala Investment Company, has signed a regional distribution agreement with Baynounah Gene Solutions, an Abu Dhabi biotechnology company that uses artificial intelligence to design molecular diagnostic test kits and manufactures them in the UAE.
The kits will be distributed through Al Ittihad Drug Store, the Mubadala Bio subsidiary that forms part of its pharmaceutical logistics business, according to a statement published by the state news agency WAM. No financial terms were disclosed.
The deal is small, but it connects two parts of the supply chain the UAE wants to build at home: designing and making diagnostics locally, and getting them to hospitals and laboratories without relying on importers. Baynounah supplies the AI-based design and production of the kits, and Al Ittihad Drug Store supplies a distribution network across the UAE and the region.
The agreement was signed at the 46th World Congress on Military Medicine in Abu Dhabi by Hamad Al Marzooqi, deputy chief executive of Mubadala Bio, and Dr Omar Najim, chief executive of Baynounah. Dr Bakheet Al Katheeri, chief executive of UAE investments at Mubadala and chairman of Mubadala Bio, attended, along with Mubadala Bio chief executive Dr Essam Mohamed and Professor Habiba Al Safar, Baynounah's vice chair.
Al Katheeri said building national capability along the pharmaceutical value chain was central to a more resilient healthcare system. Najim said Baynounah was the first company in the Middle East to produce DNA primers commercially using enzymatic DNA synthesis, and that the agreement would let it reach more customers in the UAE and the region while continuing to serve companies and research teams.
Baynounah was founded in 2025 by Sheikh Abdulla bin Mohamed bin Butti Al Hamed, Al Safar and Najim, and focuses on molecular diagnostics, synthetic biology and DNA technologies.
Mubadala Bio was launched in May 2025 and completed its acquisition of full ownership of Al Ittihad Drug Store and Global Medical Supply Chain in February 2026. In May, Al Ittihad Drug Store signed an exclusive deal to distribute L-Nutra's longevity nutrition products in the UAE. The companies did not say which Baynounah products will be distributed first or when the kits will reach customers.
Sources
- وكالة أنباء الإمارات · مبادلة بايو وبينونة توسعان إتاحة التشخيص الجزيئي المحلي بالإمارات
- Entrepreneur Middle East · Future 100 – 2025 Winner: BGS50
- Emirates News Agency (WAM) · Mubadala Bio acquires full ownership of Al Ittihad Drug Store, Global Medical Supply Chain
- Emirates News Agency (WAM) · Mubadala Bio's IDS signs exclusive distribution agreement with L-Nutra
Produced with AI assistance from the sources above. How we work
By
Nakoda News Desk
Nakoda News covers AI and business. Every story links the sources it draws on; how we work is set out in our editorial standards.



